ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.5300
-0.3000 (-6.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.8300
Open4.8200
Bid4.50 x 1100
Ask5.00 x 3000
Day's Range4.4900 - 4.9800
52 Week Range2.4900 - 6.9600
Volume148,663
Avg. Volume177,311
Market Cap209.971M
Beta (3Y Monthly)3.84
PE Ratio (TTM)N/A
EPS (TTM)-1.42
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Presslast month

    Adma Biologics: 3Q Earnings Snapshot

    On a per-share basis, the Ramsey, New Jersey-based company said it had a loss of 33 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • GlobeNewswirelast month

    ADMA Biologics Reports Third Quarter 2018 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 08, 2018 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company.

  • Zacks Small Cap Research2 months ago

    ADMA: Bivigam Delay But Will Recoup Sales Later

    On October 11th, ADMA Biologics, Inc. (ADMA) announced that the FDA considered the recently submitted Prior Approval Supplement (PAS) submission for Bivigam to be a major amendment and will require an additional two months for review. This change advances the target action date to December 18, 2018. In July 2018 ADMA indicated that the FDA had received their PAS filing for Bivigam and anticipated an October 25 PDUFA date.

  • GlobeNewswire2 months ago

    ADMA Biologics Receives PDUFA Date for RI-002

    Resubmission of Biologics License Application (“BLA”) Reinforces the Company’s Commitment to Commercialize Novel Therapies for Immune Compromised Patients to Address Unmet.

  • GlobeNewswire2 months ago

    ADMA Biologics Provides Regulatory Update for BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 11, 2018 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire2 months ago

    ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, announces that the Company’s wholly-owned subsidiary, ADMA BioCenters, has received U.S. Food and Drug Administration (“FDA”) approval for its third plasma collection center, located at 166 Ernest W Barrett Parkway, NW, Marietta, Georgia. The facility commenced operations and initiated source plasma collection in December 2017, and is now FDA licensed to collect and enter into interstate commerce to sell and use the human source plasma for further manufacturing in the U.S.

  • GlobeNewswire2 months ago

    ADMA Biologics Resubmits Biologics License Application for RI-002

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...

  • Investopedia4 months ago

    Penny Stocks to Watch for September 2018

    Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.

  • Zacks Small Cap Research4 months ago

    ADMA: FDA Submissions are Next Milestones

    ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its second quarter 2018 financial results on August 10, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under ADMA ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. On June 12, ADMA closed $40 million in equity financing followed just over six weeks later by the successful close out of the FDA compliance inspection.

  • Associated Press4 months ago

    Adma Biologics: 2Q Earnings Snapshot

    On a per-share basis, the Ramsey, New Jersey-based company said it had a loss of 35 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Zacks Small Cap Research5 months ago

    ADMA: Inspection Concluded; Product Filings Can Begin

    ADMA Biologics, Inc. (ADMA) posted a press release announcing that the FDA had successfully closed out its April inspection of the Boca Raton BioManufacturing facility and announced the target action date for Bivigam’s prior approval supplement (PAS). The favorable outcome from the FDA inspection has been eagerly awaited as it is necessary for the company to resume production of Bivigam and refile the BLA for RI-002. The FDA communicated to management that the facility received “Voluntary Action Indicated” (VAI) status as a result of the inspection.

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 26) ADMA Biologics Inc (NASDAQ: ADMA )(announced it has addressed ...

  • Here's Why ADMA Biologics Rose as Much as 27.3% Today
    Motley Fool5 months ago

    Here's Why ADMA Biologics Rose as Much as 27.3% Today

    The tiny biopharma announced a regulatory update.

  • Benzinga6 months ago

    Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 12) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • Zacks Small Cap Research6 months ago

    ADMA: Biotest Share Retirement Good for Shareholders

    ADMA Biologics, Inc. (ADMA) filed its 10-K and press release for its first quarter 2018 financial results on May 14, 2018. The highlights year to date have included the release of the first commercial batch of Nabi-HB to be manufactured under its ownership, the retirement of 8.6 million shares issued to Biotest and the grant of a patent for treating respiratory infections related to RI-002. The facility has been inspection-ready by the turn of the year and we await the arrival of the FDA inspection team.